New Meta-Analysis Demonstrates that Access to the GeneSight
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular…
Our Top 5 Analyst Questions
Myriad Genetics reported flat year-over-year sales in Q2, but the market responded positively due to results that surpassed…